The safety of venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide (ViPOR) in R/R MCL

The safety of venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide (ViPOR) in R/R MCL

BTK inhibitors for R/R MCL: current uses and insights from the ViPOR studyПодробнее

BTK inhibitors for R/R MCL: current uses and insights from the ViPOR study

OAsIs trial update: ibrutinib, venetoclax plus obinutuzumab in newly diagnosed MCLПодробнее

OAsIs trial update: ibrutinib, venetoclax plus obinutuzumab in newly diagnosed MCL

ViPOR regimen for R/R B-cell lymphomaПодробнее

ViPOR regimen for R/R B-cell lymphoma

Key novel agents for relapsed diffuse large B-cell lymphomaПодробнее

Key novel agents for relapsed diffuse large B-cell lymphoma

The role of ibrutinib in DLBCL and the value of next-generation BTK inhibitorsПодробнее

The role of ibrutinib in DLBCL and the value of next-generation BTK inhibitors

Selecting BTK inhibitors for patients with MCLПодробнее

Selecting BTK inhibitors for patients with MCL

Obinutuzumab plus venetoclax in early R/R DLBCLПодробнее

Obinutuzumab plus venetoclax in early R/R DLBCL

SYMPATICO: safety and efficacy of ibrutinib plus venetoclax for R/R MCLПодробнее

SYMPATICO: safety and efficacy of ibrutinib plus venetoclax for R/R MCL

Venetoclax, lenalidomide and rituximab in R/R MCLПодробнее

Venetoclax, lenalidomide and rituximab in R/R MCL

Real-world outcomes of brexu-cel in patients with R/R MCLПодробнее

Real-world outcomes of brexu-cel in patients with R/R MCL

TRIANGLE: ibrutinib with SOC or as a substitute to autologous transplantation in first-line MCLПодробнее

TRIANGLE: ibrutinib with SOC or as a substitute to autologous transplantation in first-line MCL

The unmet needs of patients with MCL who relapse after CAR-TПодробнее

The unmet needs of patients with MCL who relapse after CAR-T

Taking the Leap With Innovative Strategies in MCLПодробнее

Taking the Leap With Innovative Strategies in MCL

Updated results of Phase I/II BRUIN study: pirtobrutinib in covalent BTK inhibitor pretreated MCLПодробнее

Updated results of Phase I/II BRUIN study: pirtobrutinib in covalent BTK inhibitor pretreated MCL

Dr. Patel on Ibrutinib in Real-World Setting Versus Clinical TrialsПодробнее

Dr. Patel on Ibrutinib in Real-World Setting Versus Clinical Trials

Dr. Goy on Acalabrutinib Versus Ibrutinib in MCLПодробнее

Dr. Goy on Acalabrutinib Versus Ibrutinib in MCL

Does upfront treatment with venetoclax, lenalidomide, and rituximab enhance tumor responses in MCL?Подробнее

Does upfront treatment with venetoclax, lenalidomide, and rituximab enhance tumor responses in MCL?

Dr. Gasparetto on Safety Concerns With Venetoclax in Multiple MyelomaПодробнее

Dr. Gasparetto on Safety Concerns With Venetoclax in Multiple Myeloma